Interv Akut Kardiol. 2018;17(3):188-190
The EUCLID Study (Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease)
- II. interní klinika kardiologie a angiologie 1. LF UK a VFN, Praha
In patients with symptomatic peripheral artery disease, ticagrelor was not shown to be superior to clopidogrel in the reductionof cardiovascular events during a 30-month follow-up period; the only significant difference between the groups was in the rateof ischemic stroke. The rates of major bleeding were similar among the patients in the two trial groups.
Keywords: peripheral artery disease, antiplatelet therapy, clopidogrel, ticagrelor, EUCLID Study
Accepted: May 17, 2018; Published: October 1, 2018 Show citation
References
- Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057.
Go to original source... 
Go to PubMed... - Bonaca MP, Bhatt DL, Cohen M, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015; 372: 1791-1800. Go to original source... Go to PubMed...
- Berger JS, Katona BG, Jones S, et al. Design and rationale for the Effects of Ticagrelor and Clopidogrel in Patients with Peripheral Artery Disease (EUCLID) trial. Am Heart J 2016; 175: 86-93. Go to original source... Go to PubMed...
- Hiatt WR, Fowkes GR, Heizer G, et al. Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. N Engl J Med 2017; 376: 32-40. Go to original source... Go to PubMed...